Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Empagliflozin (Jardiance) for type 1 diabetes – adjunctive therapy. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Type 1 diabetes occurs when the person's own immune system attacks the pancreas and destroys the cells that produce a hormone called insulin, which is needed to regulate the body's sugar levels. Without insulin, there is too much sugar in the blood. This can cause damage to the eyes, nerves, kidneys and other tissues, and can increase the chances of heart attacks and strokes.
Empagliflozin is a drug currently used to treat type 2 diabetes. It is given as a tablet that is taken once daily. Empagliflozin is currently being studied to see if it would also work in patients with type 1 diabetes, to be taken alongside the insulin injections that patients already take.
If licensed in the UK, empagliflozin will offer type 1 diabetes patients an additional treatment option alongside insulin to maintain stable sugar levels. Indexing Status Subject indexing assigned by CRD MeSH Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides; Humans Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000819 Date abstract record published 22/06/2016 |